The present invention relates to a process for the preparation of amorphous Selexipag from Selexipag crystalline salts using a solvent.

The present invention relates to a process for the preparation of amorphous Selexipag from Selexipag crystalline salts using a solvent.

The present invention relates to a process for the preparation of amorphous Selexipag from Selexipag crystalline salts using a solvent.

The present invention relates to a process for the preparation of amorphous Selexipag from Selexipag crystalline salts using a solvent.

A method for synthesizing levomethadone hydrochloride including producing (R)-2-(dimethylamino)propan-1-ol by reducing N,N-dimethyl-D-alanine using borax, forming (R)-1-chloro-N,N-dimethylpropane-2-amine hydrochloride by chlorinating the (R)-2-(dimethylamino)propan-1-ol, synthesizing levomethadone nitrile hydrochloride by mixing the (R)-1-chloro-N,N-dimethylpropane-2-amine and diphenylacetonitrile with potassium t-butoxide and producing levomethadone hydrochloride by exposing the levomethadone nitrile hydrochloride to a Grignard reagent.

A method for synthesizing levomethadone hydrochloride including producing (R)-2-(dimethylamino)propan-1-ol by reducing N,N-dimethyl-D-alanine using borax, forming (R)-1-chloro-N,N-dimethylpropane-2-amine hydrochloride by chlorinating the (R)-2-(dimethylamino)propan-1-ol, synthesizing levomethadone nitrile hydrochloride by mixing the (R)-1-chloro-N,N-dimethylpropane-2-amine and diphenylacetonitrile with potassium t-butoxide and producing levomethadone hydrochloride by exposing the levomethadone nitrile hydrochloride to a Grignard reagent.

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.

An object of the present invention is to provide an n-type thermoelectric conversion layer, which has a high power factor and exhibits excellent performance stability, a thermoelectric conversion element including the n-type thermoelectric conversion layer, and a composition for forming an n-type thermoelectric conversion layer used in the n-type thermoelectric conversion layer. The n-type thermoelectric conversion layer of the present invention contains carbon nanotubes and an amine compound which is represented by General Formula (1) or (2) and has a C log P value of 2.0 to 8.2. ##STR00001##

An object of the present invention is to provide an n-type thermoelectric conversion layer, which has a high power factor and exhibits excellent performance stability, a thermoelectric conversion element including the n-type thermoelectric conversion layer, and a composition for forming an n-type thermoelectric conversion layer used in the n-type thermoelectric conversion layer. The n-type thermoelectric conversion layer of the present invention contains carbon nanotubes and an amine compound which is represented by General Formula (1) or (2) and has a C log P value of 2.0 to 8.2. ##STR00001##